nejm semaglutide heart failure Read the full results of the STEP-HFpEF trial, presented at #ESCCongress: Original Article: in Patients with and Obesity https://t.co/a3ovagJquz Editorial: Heart Failure with Preserved Ejection Fraction — A Metabolic Semaglutide and Cardiovascular Outcomes in

After losing weight, "there's more cardiometabolic benefits, the blood pressure goes down further, the insulin goes down further, lipids improve further." Ahmad said the clinical trials will provide important insights for physicians treating patients, as well as for insurance companies and governments when determining whether to include weight loss drugs in their coverage

People using Semaglutide (the active ingredient in Ozempic) have lost an average of about 15% of their body weight over roughly 68 weeks in clinical research

If you already take one of these drugs for diabetes or weight loss, it might be a good time to try quitting

Ioannidou: [00:18:01] And I was like, huh, that's an interesting term to start a paper